Phase 3 Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of skin cancer called invasive cutaneous squamous cell carcinoma (CSCC), confirmed by a laboratory test on a tissue sample.
- People whose skin cancer tumour measures at least 1 cm but no more than 2 cm across, and is located on the head, neck, hand, or the front of the lower leg (shin area).
- People whose doctors have determined that surgery is an appropriate treatment, and where the planned surgery involves carefully checking all the edges of the removed tissue to make sure no cancer cells are left behind (such as a technique called Mohs surgery).
- People who are generally in good physical health and able to carry out daily activities, based on a standard medical assessment scale (confirm with trial site).
- People whose liver, kidneys, and blood cell counts are all working within acceptable ranges, as assessed by the trial team.
Who may not be able to join:
- People whose skin lesion is a specific type of growth or cancer other than invasive CSCC — including certain rarer subtypes of skin cancer or a pre-cancerous condition called Bowen's disease (confirm with trial site for borderline cases).
- People who have had a significant autoimmune disease (where the immune system attacks the body) requiring strong medicines to suppress the immune system, either currently or within the past 5 years.
- People who have had inflammation of the lungs not caused by an infection, within the past 5 years.
- People whose lesion, or another skin cancer lesion, is located on the lip's red/pink border, inside the mouth, or inside the nose.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals
Phone: 844-734-6643
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Event-Free Survival (EFS) as assessed by the investigator; EFS as assessed by the investigator
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.